One-stop Solutions for Antibody-Drug Conjugates (ADCs) Formulation Development
InquiryAn ADC is a complex molecular entity composed of three essential components: a monoclonal antibody, a cytotoxic drug payload, and a linker molecule that connects them, which have high cytotoxic activity to monoclonal antibodies through chemical, biological and other methods, and use the specific affinity between antibodies and antigens to target the linked drugs to tumor cells, so as to enhance the therapeutic activity of antibodies and improve the targeting of cytotoxic drugs to kill tumor cells. At CD Formulation, we possess the most advanced equipment and unique R&D expertise to provide personalized antibody coupling services according to customers' specific needs promptly. Moreover, we monitor our products according to strict quality control standards during development and optimization processes to ensure our customers receive first-class services and products.
Fig1. Mechanism of action of ADCs
Our One-stop Solutions for ADCs Formulation Development Include But Not Limited to:
With our R&D capabilities, CD Formulation has built an ADCs one-stop service team, and our high Activization team and Chemical Macromolecule department can generate, design, evaluate and optimize your antibody drug conjugate (ADC) with years of project experience.
With years of experience in ADCs design, production, and analysis, CD Formulation has gained significant knowledge in ADCs antibody screening.we provide professional antibody screening services including the consultation in antigen selection, antigen-specific antibody screening, internalizing antibody selection, as well as proof-of-concept feasibility validation using "Anti-Ab ADCs". In addition, our expert technical team has also developed a series of antibody pre-screening kits to expedite the identification of antibodies suitable for ADC candidates. If you have any questions about antibody screening, we are more than happy to share our experience and help you with this tragically important step in ADCs development.
Our expert technical teams use conventional chemistries to provide customized design and synthesis of linkers, these linkers embody a wide range of structures and functionalities, which is designed for the conjugation of a broad spectrum of antibodies and toxins. More importantly, our linkers allow the conjugation process to be performed in a precise and controlled fashion, easing the batch-to-batch product manufacturing and quality control.
- ADCs Cytotoxic Drug Payload
We provide a wide variety of tubulin inhibitors and DNA-alkylating agents that have proven to be payloads for commercial use. We can also provide cGMP production of 100g quantities. In addition, we have a range of proprietary toxins that can be tested and licensed upon request.
We have the ability to independently undertake the in-depth characterization of ADCs drug products and the analysis and evaluation of various ADCs drug quality attributes, providing customers with a wide range of analytical services such as method development, concentration determination with UV, drug-to-antibody Ratio (DAR) and unconjugated antibody by HIC-HPLC, aggregate analysis by SEC-HPLC, residual drug composition by RP-HPLC, endotoxin, SDS PAGE, cell killing assays, ELISA, stability studies. We also have CMC development and technical transfer capabilities.
About CD Formulation
Under our one-stop service platform system, we improve the efficiency of ADCs drug development and reduce the difficulty of supply chain management for innovative pharmaceutical companies. With world-class expertise in ADCs development, our service team can solve various problems in the development of ADCs for our customers and partners. If you have any ADCs requirements, please contact us by phone or email, our colleagues will reply to you within three working days.
Related Services
